TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01090297

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: S8 Spirit 2
Description: 3 types of Continuous Positive Airway Pressure (CPAP) device: S8 Spirit 2, Somnosmart 2, Remstar Auto.~These 3 types of CPAP can be set in both mode of pressure.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: S8 Spirit 2
Description: 3 types of Continuous Positive Airway Pressure (CPAP) device: S8 Spirit 2, Somnosmart 2, Remstar Auto.~These 3 types of CPAP can be set in both mode of pressure.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Somnosmart 2
Description: 3 types of Continuous Positive Airway Pressure (CPAP) device: S8 Spirit 2, Somnosmart 2, Remstar Auto.~These 3 types of CPAP can be set in both mode of pressure.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Somnosmart 2
Description: 3 types of Continuous Positive Airway Pressure (CPAP) device: S8 Spirit 2, Somnosmart 2, Remstar Auto.~These 3 types of CPAP can be set in both mode of pressure.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Remstar Auto
Description: 3 types of Continuous Positive Airway Pressure (CPAP) device: S8 Spirit 2, Somnosmart 2, Remstar Auto.~These 3 types of CPAP can be set in both mode of pressure.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Remstar Auto
Description: 3 types of Continuous Positive Airway Pressure (CPAP) device: S8 Spirit 2, Somnosmart 2, Remstar Auto.~These 3 types of CPAP can be set in both mode of pressure.
Study: NCT03334422

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baricitinib
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baricitinib
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baricitinib
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered orally
Study: NCT00907764

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: regadenoson
Description: 400 ug, IV
Study: NCT03920098

Intervention type: OTHER
Intervention: Nutrition and mental health during pregnancy
Description: Altered metabolic milieu is defined as a fasting glucose level \>100 mg/dL at the first trimester of pregnancy by national guidelines. Altered metabolic milieu during the second trimester (24-28 weeks of pregnancy) is defined as a fasting glucose levels \> 92 mg/dL and/or plasma glucose levels \> 153 mg/dL two hours after load in the oral glucose tolerance test according to ADA guidelines or a fasting glucose \>100 mg/dL and/or \> 140 mg/dL two hours after load in the oral glucose tolerance test according to national guidelines. The COVID-19 pandemic is considered as a natural nutritional and mental health exposure.
Study: NCT03835962

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NeuroCatch™ Platform
Description: NeuroCatch Platform™ consists of software and hardware that captures brain health information. The platform intends to provide a quick, portable and easy to use solution for the acquisition, display, analysis, storage, reporting and management of electroencephalograph (EEG) and event-related potential (ERP) information.
Study: NCT05963009

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: baxdrostat (formerly CIN-107) oral solution
Description: 5 mg single dose of baxdrostat given as either a solution or tablet in either the fed or fasted state, depending on the arm of the study

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: baxdrostat (formerly CIN-107) oral solution
Description: 5 mg single dose of baxdrostat given as either a solution or tablet in either the fed or fasted state, depending on the arm of the study

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: baxdrostat (formerly CIN-107) oral solution
Description: 5 mg single dose of baxdrostat given as either a solution or tablet in either the fed or fasted state, depending on the arm of the study
Study: NCT04510298

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SP-624
Description: Oral Capsule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral Capsule
Study: NCT02417649

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1. The placebo will be administered for a period of three months. The first ten days of each month, one tablet per day will be given. The tablet will be melted under the tongue. After the ten day therapy, a twenty day of rest will be provided. Then the second and the third month the administration schedule will be identical.~2. Three months of rest, according to the indications, will be allowed.~3. A second cycle (the same as point 1.) will be performed~4. A second three month rest (according to point 2.) will be provided.
Study: NCT03334422

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally
Study: NCT03304275

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tdap
Description: Randomized controlled trial of 2 strategies to provide adults with the Tdap vaccine

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tdap
Description: Randomized controlled trial of 2 strategies to provide adults with the Tdap vaccine
Study: NCT03231137

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: PRGF/ATV
Description: Atorvastatin (ATV) loaded on plasma rich in growth factor (PRGF) Derived Fibrin Scaffold

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATV gel
Description: Atorvastatin gel

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PRF
Description: Platelet rich fibrin

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PRGF
Description: plasma rich in growth factor
Study: NCT02417649

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ismigen
Description: 1. The tablet will be administered for a period of three months. The first ten days of each month, one tablet per day will be given. The tablet will be melted under the tongue. After the ten day therapy, a twenty day of rest will be provided. Then the second and the third month the administration schedule will be identical.~2. Three months of rest, according to the indications, will be allowed.~3. A second cycle (the same as point 1.) will be performed~4. A second three month rest (according to point 2.) will be provided.
Study: NCT03865953

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LAT8881
Description: LAT8881 oral capsule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo oral capsule
Study: NCT01514851

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lanthanum carbonate (BAY77-1931)
Study: NCT00693485

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 400 ug Brimonidine Implant
Description: 400 ug Brimonidine Tartrate Posterior Segment Drug Delivery system; Applicator System at Day 1 in study eye.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 200 ug Brimonidine Implant
Description: 200 ug Brimonidine Tartrate Posterior Segment Drug Delivery system; Applicator System at Day 1 in study eye.

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Sham (no implant)
Description: Sham Posterior Segment Drug Delivery system; Applicator System at Day 1 in study eye.
Study: NCT00833014

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dynamic Annuloplasty Ring (with option to adjust off-pump)
Description: Annuloplasty device repair of mitral valve regurgitation with option to adjust device post implant.
Study: NCT02844894

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esmolol

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: normal saline
Study: NCT01031017

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: progesterone
Description: ovules, 200mg per vagina, once a day from 18 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study: NCT03942367

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active Device (vPatch)
Description: Electrical stimulation inducing motor response at the pelvic-floor muscles. Stimulation will be delivered by vPatch device configured to motor intensity.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Device (vPatch)
Description: Electrical stimulation inducing sensory response at the perineum.Stimulation will be delivered by vPatch device configured to sensory intensity.
Study: NCT02306421

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: RPH with the simplified Milligan-Morgan
Description: RPH is a new therapy for hemorrhoid following the improvement of rubber band ligation. The treatment principle is: shrinkage of mucous membrane after the ligation, lift of anal cushion, the local inflammatory response resulting in adhesion of mucosa and submucosa and shallow muscle layer, anal cushion fixing to a higher position, at the same time by using the elastic contraction of automatic elastic line partly blocking blood supply of Internal hemorrhoids or reducing venous stasis, decreasing congestion hypertrophy of hemorrhoids. Simplified Milligan-Morgan is a surgical option which was improved and developed by Professor He,well-known traditional Chinese doctor from Hunan province, based on Milligan-Morgan in 1971.The operation method is simple, the operation time is shortened.
Study: NCT01514851

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Calcium carbonate
Study: NCT02768597

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ReUnion System with a Large-Diameter Glenosphere +2 mm offset
Description: Primary Reverse Shoulder Arthroplasty using the ReUnion System with a Large-Diameter Glenosphere +2 mm offset

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ReUnion System with a Small-Diameter Glenosphere +2 mm offset
Description: Primary Reverse Shoulder Arthroplasty using the ReUnion System with a Small-Diameter Glenosphere +2 mm offset

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ReUnion System with a Large-Diameter Glenosphere +6 mm offset
Description: Primary Reverse Shoulder Arthroplasty using the ReUnion System with a Large-Diameter Glenosphere +6 mm offset

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ReUnion System with a Small-Diameter Glenosphere +6 mm offset
Description: Primary Reverse Shoulder Arthroplasty using the ReUnion System with a Small-Diameter Glenosphere +6 mm offset
Study: NCT02784743

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ''albendazole'' and ''ivermectin''
Description: annual single dose administration of albendazole 400mg and ivermectin 150ug/kg of weight (according to the height)
Study: NCT02968706

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High Flow Nasal Cannula
Description: Heated humidified high flow oxygen of 50 L/min at FiO2 of 40%

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Nasal Cannula
Description: Supplemental oxygen of 2-5 L/min

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Patient satisfaction questionnaire
Description: Questionnaire

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient satisfaction questionnaire
Description: Questionnaire
Study: NCT01476683

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Racecadotril
Description: Film-coated tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Racecadotril
Description: Racecadotril Powder Blend

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Racecadotril
Description: Marketed Capsule

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Racecadotril
Description: Marketed Film-coated Tablet
Study: NCT02306421

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PPH with the simplified Milligan-Morgan
Description: According to anal cushion down theory of the formation of hemorrhoids, the Italy scholar Longo pioneered a new method for the treatment of circular prolapsed internal hemorrhoids In 1998.Its principle is resection of lower rectal mucosa and submucosa of the intestinal wall tissue in the ring above the hemorrhoids through surgical staples,anastomosis of the proximal and distal mucosa , lifting and fixing down anal cushion, recovering to the normal anatomical position.Simplified Milligan-Morgan is a surgical option which was improved and developed by Professor He,well-known traditional Chinese doctor from Hunan province, based on Milligan-Morgan in 1971.The operation method is simple, the operation time is shortened.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: RPH
Description: RPH is a new therapy for hemorrhoid following the improvement of rubber band ligation.The treatment principle is: shrinkage of mucous membrane after the ligation, lift of anal cushion, the local inflammatory response resulting in adhesion of mucosa and submucosa and shallow muscle layer , anal cushion fixing to a higher position, at the same time by using the elastic contraction of automatic elastic line partly blocking blood supply of Internal hemorrhoids or reducing venous stasis, decreasing congestion hypertrophy of hemorrhoids , making hemorrhoidal lump shrink, thus eliminating bleeding and prolapse symptoms of hemorrhoid.It is suitable for internal hemorrhoids in every period and internal hemorrhoids part of mixed hemorrhoid.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PPH
Description: According to anal cushion down theory of the formation of hemorrhoids, the Italy scholar Longo pioneered a new method for the treatment of circular prolapsed internal hemorrhoids In 1998.Its principle is resection of lower rectal mucosa and submucosa of the intestinal wall tissue in the ring above the hemorrhoids through surgical staples,anastomosis of the proximal and distal mucosa , lifting and fixing down anal cushion, recovering to the normal anatomical position
Study: NCT00883298

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: temozolomide and bevacizumab
Description: oral temozolomide 100 mg/m2 days 1-5 \& 15-19 every 28-day cycle plus intravenous bevacizumab 10 mg/kg days 1 \& 5 every 28-day cycle
Study: NCT02607787

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: The exercise programme aims to gradually increase participants physical activity levels so that they start achieving the recommended levels of at least 150 minutes moderate intensity aerobic activity per week and strengthening exercise for all major muscle groups at least twice per week.

Intervention type: OTHER
Group type: OTHER
Intervention: Control
Description: The control group will receive usual care whilst attending for the same 4 visits as the intervention group and have the same outcome measures tested. They will however receive the intervention information on their last visit.
Study: NCT01392703

Intervention type: DRUG
Group type: OTHER
Intervention: Dasatinib as tablets
Description: 2 50-mg tablets plus 240 mL noncarbonated, nonrefrigerated water. Oral, single dose, 1 day

Intervention type: DRUG
Group type: OTHER
Intervention: Dasatinib as liquid
Description: 100 mg administered as 10 mL of liquid drug (10 mg/mL) plus 230 mL noncarbonated, nonrefrigerated water. Oral, single dose, 1 day

Intervention type: DRUG
Group type: OTHER
Intervention: Dasatinib as dispersed tablets
Description: 2 50-mg dispersed tablets in 30 mL of 100% orange juice followed by 15 mL of orange juice plus 195 mL noncarbonated, nonrefrigerated water. Liquid (oral solution), single dose, 1 day.
Study: NCT00470197

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: alvocidib
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mitoxantrone hydrochloride
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative study
Study: NCT05201053

Intervention type: DIAGNOSTIC_TEST
Intervention: Exploratory for different markers
Description: Test biomarkers for development of mild, moderate or severe disease

Intervention type: DIAGNOSTIC_TEST
Intervention: Exploratory for different markers
Description: Test biomarkers for development of mild, moderate or severe disease

Intervention type: DIAGNOSTIC_TEST
Intervention: Exploratory for different markers
Description: Test biomarkers for development of mild, moderate or severe disease
Study: NCT03721705

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Renew NCP-5
Description: Treatment will be given 3-5 times a week for a total of 35 treatments over 12 weeks.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Renew NCP-5
Description: Treatment will be given 3-5 times a week for a total of 35 treatments over 12 weeks.
Study: NCT03078335

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Glove based care
Description: Described in Experimental Arm: Glove based care
Study: NCT02306421

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Milligan-Morgan
Description: Milligan-Morgan surgery ,created in 1937 by Milligan etc,whose essence is to excise hemorrhoids of increasing prolapse in anatomy has good curative effect, low recurrence.It is currently the most common clinical surgery.
Study: NCT03067259

Intervention type: OTHER
Group type: OTHER
Intervention: Exposure Group
Description: Surgeries of high or low impact. They could be local , regional o general anesthesia; sedation or a combination of both.
Study: NCT01967979

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO5285119
Description: Single dose, alone and after repeated administration of itraconazole or fluoxetine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO5285119
Description: Single dose, alone and after repeated administration of itraconazole or fluoxetine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluoxetine
Description: Multiple doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: itraconazole
Description: Multiple doses
Study: NCT02469168

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Recell
Description: ReCell Treatment over wound pretreated with INTEGRA™ MBWM Wound Matrix

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Standard meshed split thickness skin graft over wound pretreated with INTEGRA™ MBWM Wound Matrix
Study: NCT00433017

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Verteporfin Photodynamic Therapy
Description: After a 10-minute intravenous infusion of verteporfin at a dose of 6 mg/m\^2 body surface area, verteporfin was activated by light application of 50 J/cm\^2 to the study eye, begun 15 minutes after the start of the infusion.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ranibizumab
Description: Ranibizumab 0.5 mg (0.05 mL of 10 mg/mL solution for injection) administered as an intravitreal injection
Study: NCT03078335

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care - Hand Hygiene
Description: Hand Hygiene - hand washing with soap and water, or alcohol based hand rub
Study: NCT04338412

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ProSeal-LMA™
Description: It is a second generation LMA that is commonly used among all other LMAs

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ProSeal-LMA™
Description: It is a second generation LMA that is commonly used among all other LMAs

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ProSeal-LMA™
Description: It is a second generation LMA that is commonly used among all other LMAs
Study: NCT03585088

Intervention type: DEVICE
Group type: OTHER
Intervention: surgical pleth index
Description: All patients applied surgical pleth index after recovery of spontaneous breathing at the time of peritoneum and skin closure under Bispectral index score \<=60.
Study: NCT01843777

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard-of-Care
Description: the standard of care in audiologic practice

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Treatment
Description: motivational interviewing
Study: NCT01746147

Intervention type: OTHER
Intervention: No intervention and study treatment
Study: NCT03721172

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apremilast
Description: Apremilast, oral, twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apremilast
Description: Apremilast, oral, twice daily

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo, oral, twice daily
Study: NCT02562157

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: HYALURONIQUE ACIDE
Description: Intradermal delivery of fractional CO2 laser-assisted hyaluronic acid in facial skin contouring
Study: NCT00420784

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telaprevir
Description: tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telaprevir
Description: tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telaprevir
Description: tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ribavirin
Description: tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pegylated Interferon Alfa 2a
Description: Solution for injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated Interferon Alfa 2a
Description: Solution for injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated Interferon Alfa 2a
Description: Solution for injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated Interferon Alfa 2a
Description: Solution for injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo
Description: Tablet
Study: NCT03859817

Intervention type: OTHER
Intervention: Comparison of eGFR values and ketonemia in diabetic patients
Description: To verify if there is a correlation between the level of ketones and an alteration of the renal function in the diabetic patient, the values of the prognostic markers indicated in the protocol and the data downloaded by the glucometers will be evaluated in addition to the blood tests of the patients

Intervention type: OTHER
Intervention: Comparison of eGFR values and ketonemia in diabetic patients
Description: To verify if there is a correlation between the level of ketones and an alteration of the renal function in the diabetic patient, the values of the prognostic markers indicated in the protocol and the data downloaded by the glucometers will be evaluated in addition to the blood tests of the patients
Study: NCT04627051

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Atherectomy and balloon angioplasty
Description: Atherectomy and balloon angioplasty of arterial-venous graft stenosis
Study: NCT04205357

Intervention type: DRUG
Group type: OTHER
Intervention: Sulfasalazine
Description: Sulfasalazine combined with stereotactic radiosurgery